- Investing Ideas
- /
- Global Undervalued Stocks Based On Cash Flows
Global Undervalued Stocks Based On Cash Flows
Results
921
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
921 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
DE | CA$5.96 | -3.9% | -37.6% | CA$117.5m | CA$7.44 | PE45.7x | E55.1% | 9.1% | Capital Goods | ||
ABBV | US$192.97 | 9.9% | 10.4% | US$338.8b | US$204.90 | PE79.7x | E25.3% | 3.4% | Pharmaceuticals & Biotech | ||
VRRM | US$25.88 | -3.2% | 15.5% | US$4.3b | US$29.00 | PE42.2x | E23.1% | n/a | Commercial Services | ||
605108 | CN¥20.86 | -3.7% | -24.1% | CN¥5.4b | CN¥25.97 | PE29.3x | E44.9% | 2.0% | Consumer Services | ||
ONB | US$24.45 | 2.8% | 53.9% | US$7.7b | US$27.61 | PB1.3x | E33.1% | 2.3% | Banks | ||
ERIC B | SEK 83.14 | -2.6% | 46.9% | SEK 277.0b | SEK 84.42 | PE13853.9x | E46.6% | 3.4% | Tech | ||
FACE | €2.24 | 2.3% | 12.0% | €50.2m | €2.00 | PS1.6x | E72.6% | n/a | Software | ||
981 | HK$47.90 | 26.1% | 231.7% | HK$509.2b | HK$29.00 | PE87.7x | E23.1% | n/a | Semiconductors | ||
SFR | AU$10.33 | 7.2% | 44.7% | AU$4.7b | AU$10.57 | PS3.2x | E40.7% | 0% | Materials | ||
A248070 | ₩18,800.00 | -0.8% | -31.1% | ₩905.0b | ₩31,625.00 | PE20.4x | E50.0% | n/a | Tech | ||
3922 | JP¥2,241.00 | 2.7% | 2.8% | JP¥30.2b | JP¥3,200.00 | PE25.8x | E20.4% | 0.5% | Media | ||
MEDX | CHF 12.58 | 2.8% | -27.2% | CHF 513.1m | CHF 25.00 | PS1.1x | E59.6% | 4.0% | Healthcare | ||
HMSP | Rp580.00 | -4.1% | -34.1% | Rp67.5t | Rp819.50 | PE9.5x | E12.3% | 11.9% | Food, Beverage & Tobacco | ||
2762 | NT$90.10 | -2.8% | -7.1% | NT$9.9b | NT$122.33 | PE25x | E45.7% | 2.5% | Consumer Services | ||
605305 | CN¥27.93 | -2.2% | 10.1% | CN¥5.9b | CN¥36.04 | PE18.2x | E24.9% | 1.4% | Capital Goods | ||
603707 | CN¥13.36 | -1.1% | -4.0% | CN¥21.6b | CN¥17.83 | PS5.6x | E69.6% | 0.7% | Pharmaceuticals & Biotech | ||
688561 | CN¥31.52 | 25.9% | -0.6% | CN¥21.5b | CN¥31.51 | PE181.2x | E38.5% | n/a | Software | ||
VCT | UK£9.89 | -1.1% | -26.4% | UK£860.0m | UK£12.47 | PE50x | E29.4% | 6.0% | Materials | ||
QUIS | CA$0.56 | 0% | 103.6% | CA$155.1m | CA$0.57 | PS0.9x | E182.4% | n/a | Software | ||
REACH | NOK 8.30 | 3.8% | 89.9% | NOK 2.3b | NOK 10.03 | PE9.7x | E44.4% | 4.3% | Energy | ||
PRVA | US$22.69 | 0.7% | 11.8% | US$2.8b | US$26.00 | PE212.3x | E34.2% | n/a | Healthcare | ||
300702 | CN¥17.41 | 0.5% | 3.1% | CN¥6.0b | CN¥22.42 | PE137.1x | E71.4% | 0.3% | Pharmaceuticals & Biotech | ||
1503 | NT$178.00 | -4.6% | 45.9% | NT$92.7b | NT$290.00 | PE32.2x | E34.9% | 1.7% | Capital Goods | ||
NWBI | US$13.39 | 3.0% | 14.1% | US$1.7b | US$13.88 | PB1.1x | E33.6% | 6.0% | Banks |